Balasubramanyam Seshan

781-810 (out of 1193)

Delta Air Lines Shares Hit New Low

Shares of Delta Air Lines Inc. (NYSE: DAL) touched a new 52-week low of $9.31 on Wednesday. The company said its load factor for the month of March declined 4.5 percentage points to 79.7 percent from 84.2 percent last year.

Cubist Pharma Shares Hit New High

Shares of Cubist Pharmaceuticals Inc. (CBST) touched a new 52-week high of $30.02 on Wednesday morning. Optimer Pharmaceuticals Inc. (OPTR) said it has entered an exclusive two-year co-promotion agreement with Cubist to market Dificid in the U.S.

Questcor Pharma Shares Hit Life-Time High

Shares of Questcor Pharmaceuticals, Inc. (QCOR) touched a new life-time high of $18.50 on Tuesday. The company issued preliminary metrics for the first quarter, whereby it projects a 115 percent first quarter surge in sales of its main drug H.P. Acthar Gel that is used to treat certain disorders with an inflammatory component.

Five Reasons Why Apple Should Delay iPhone 5 Launch

Barclays Capital said it has received many questions over the past week around thoughts on the potential timing of Apple Inc.'s iPhone 5. In summary, Reitzes believes it may make sense for Apple to launch this version of the iPhone a little later than usual for five reasons.

Apple's Cloud Tunes Likely Coming Soon

Apple Inc. is widely expected to release its own iTunes-related cloud strategy soon likely integrating its MobileMe services and taking advantage of its investments in its North Carolina data center, Barcalys Capital said.

Calix Shares to Sell Off Modestly on Tuesday: Analyst

Jefferies & Co. expects that shares of Calix, Inc. (NYSE: CALX) will sell off modestly on Tuesday as investors contemplate another round of very conservative guidance from the company. The brokerage reiterated its buy rating on shares of Calix, while increasing its price target to $24.50 from $16.

VeriSign to Repurchase More Shares: Analyst

Wedbush Securities expects VeriSign Inc. (NASDAQ: VRSN) to continue to return capital to investors through 2011. The brokerage maintained its neutral rating on shares of VeriSign with a price target of $38.

Pre-Market NASDAQ Movers (MSSR, VVUS, OREX, CIGX, OPTR, OVTI, DEPO, AMTD, LOGI, CHKP)

The top pre-market NASDAQ Stock Market gainers are: McCormick & Schmick's Seafood Restaurants, VIVUS, Orexigen Therapeutics, Star Scientific, and Optimer Pharmaceuticals. The top pre-market NASDAQ Stock Market losers are: OmniVision Technologies, DepoMed, TD AMERITRADE Holding, Logitech International, and Check Point Software Technologies.

Top 10 Hottest New Restaurants in U.S. (SLIDESHOW)

The restaurant reservation platform OpenTable Inc. announced the list of top 10 hottest new restaurants, which are among the 50 winners of OpenTable's Diners' Choice Awards for the Top Hot Spot Restaurants in the United States.

Strong OTN Growth Attract New Players (PMCS, BRCM, NETL, ALTR)

Auriga USA LLC expects optical transport network to get increasingly crowded with players like PMC-Sierra Inc. (PMCS), Broadcom Corp. (BRCM), NetLogic Microsystems Inc. (NETL), and potentially even FPGA (field-programmable gate array) vendor Altera Corp. (ALTR) vying to build application specific standard products (ASSP) to target this space.

Biogen Idec Shares Hit New High on Start of Late-Stage ALS Drug Trial

Shares of Biogen Idec Inc. (NASDAQ: BIIB) touched a new 52-week high of $73.53 on Thursday. The company and its partner Knopp Biosciences announced enrollment of the first patient in EMPOWER, a multi-national Phase III study evaluating the efficacy, safety and pharmacokinetics of dexpramipexole in patients with amyotrophic lateral sclerosis (ALS).

Synthesis Energy Shares Hit New High on China Investment

Shares of Synthesis Energy Systems, Inc. (NASDAQ: SYMX) touched a new 52-week high of $3.12 on Thursday. The company has agreed with China Energy Industry Holding Group Co. Limited for a cash investment of about $83.8 million to support the company's business strategy in China, including project development and investment.

Near-Term Generic For Teva's Copaxone Still Unlikely: Analyst

RBC Capital Markets continues to believe that Teva Pharmaceutical Industries Ltd.'s (NASDAQ: TEVA) generic Copaxone is unlikely in the near term. The brokerage also said FDA denied Copaxone Citizen Petition (CP) as it is premature to make a decision on generic approvability.

Pages